The Immune Response to SARS-CoV-2 in People with HIV

Overview

Journal Cell Mol Immunol

Date 2023 Oct 11

PMID 37821620

Authors

Maxine A Hoft

Wendy A Burgers

Catherine Riou

Affiliations

Soon will be listed here.

Abstract

This review examines the intersection of the HIV and SARS-CoV-2 pandemics. People with HIV (PWH) are a heterogeneous group that differ in their degree of immune suppression, immune reconstitution, and viral control. While COVID-19 in those with well-controlled HIV infection poses no greater risk than that for HIV-uninfected individuals, people with advanced HIV disease are more vulnerable to poor COVID-19 outcomes. COVID-19 vaccines are effective and well tolerated in the majority of PWH, though reduced vaccine efficacy, breakthrough infections and faster waning of vaccine effectiveness have been demonstrated in PWH. This is likely a result of suboptimal humoral and cellular immune responses after vaccination. People with advanced HIV may also experience prolonged infection that may give rise to new epidemiologically significant variants, but initiation or resumption of antiretroviral therapy (ART) can effectively clear persistent infection. COVID-19 vaccine guidelines reflect these increased risks and recommend prioritization for vaccination and additional booster doses for PWH who are moderately to severely immunocompromised. We recommend continued research and monitoring of PWH with SARS-CoV-2 infection, especially in areas with a high HIV burden.

Citing Articles

Dynamic SARS-CoV-2-specific B-cell and T-cell responses induced in people living with HIV after a full course of inactivated SARS-CoV-2 vaccine.

Wang X, Yang X, Zhang X, Yan H, Jin J, Ma Z Front Immunol. 2025; 16:1554409.

PMID: 40070834 PMC: 11893571. DOI: 10.3389/fimmu.2025.1554409.

Coronavirus replicase epitopes induce cross-reactive CD8 T cell responses in SARS-CoV-2-naive people with HIV-1.

Schmidt K, Geissler P, Schuster E, Schulein C, Harrer E, Schonau V iScience. 2025; 28(3):111949.

PMID: 40034846 PMC: 11872457. DOI: 10.1016/j.isci.2025.111949.

Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study.

Garrett N, Tapley A, Hudson A, Dadabhai S, Zhang B, Mgodi N EClinicalMedicine. 2025; 80:103054.

PMID: 39902315 PMC: 11788791. DOI: 10.1016/j.eclinm.2024.103054.

Prevalence of post-acute sequelae of SARS-CoV-2 infection in people living with HIV: a systematic review with meta-analysis.

Pouliopoulou D, Billias N, MacDermid J, Miller E, OBrien K, Quinn K EClinicalMedicine. 2025; 79():102993.

PMID: 39802304 PMC: 11721256. DOI: 10.1016/j.eclinm.2024.102993.

COVID-19 Vaccination and Transient Increase in CD4/CD8 Cell Counts in People with HIV: Evidence from China.

Li Y, Lin Y, Yi Y, Zhu N, Cui X, Li X Vaccines (Basel). 2025; 12(12.

PMID: 39772028 PMC: 11680300. DOI: 10.3390/vaccines12121365.

References

Smith C, Ashby B . Antigenic evolution of SARS-CoV-2 in immunocompromised hosts. Evol Med Public Health. 2023; 11(1):90-100. PMC: 10061940. DOI: 10.1093/emph/eoac037. View

Ngalamika O, Lidenge S, Mukasine M, Kawimbe M, Kamanzi P, Ngowi J . SARS-CoV-2-specific T cell and humoral immunity in individuals with and without HIV in an African population: a prospective cohort study. Int J Infect Dis. 2022; 127:106-115. PMC: 9741763. DOI: 10.1016/j.ijid.2022.12.009. View

Liu Y, Han J, Li X, Chen D, Zhao X, Qiu Y . COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity. Vaccines (Basel). 2021; 9(12). PMC: 8706383. DOI: 10.3390/vaccines9121458. View

Juno J, Tan H, Lee W, Reynaldi A, Kelly H, Wragg K . Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med. 2020; 26(9):1428-1434. DOI: 10.1038/s41591-020-0995-0. View

Goel R, Painter M, Apostolidis S, Mathew D, Meng W, Rosenfeld A . mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021; 374(6572):abm0829. PMC: 9284784. DOI: 10.1126/science.abm0829. View

Gazzola L, Tincati C, Bellistri G, Monforte A, Marchetti G . The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis. 2009; 48(3):328-37. DOI: 10.1086/595851. View

Nomah D, Reyes-Uruena J, Diaz Y, Moreno S, Aceiton J, Bruguera A . Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. Lancet HIV. 2021; 8(11):e701-e710. PMC: 8514194. DOI: 10.1016/S2352-3018(21)00240-X. View

Perez-Alos L, Almagro Armenteros J, Madsen J, Hansen C, Jarlhelt I, Hamm S . Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. Nat Commun. 2022; 13(1):1614. PMC: 8960902. DOI: 10.1038/s41467-022-29225-4. View

Loubet P, Wittkop L, Ninove L, Chalouni M, Barrou B, Blay J . One-month humoral response following two or three doses of messenger RNA coronavirus disease 2019 vaccines as primary vaccination in specific populations in France: first results from the Agence Nationale Recherche contre le Sida (ANRS)0001S.... Clin Microbiol Infect. 2022; 29(3):388.e1-388.e8. PMC: 9562615. DOI: 10.1016/j.cmi.2022.10.009. View

10.

Messali S, Giovanetti M, Ciccozzi M, Caruso A, Caccuri F . Detection of SARS-CoV-2 Alpha variant in a severely immunocompromised HIV-1-infected patient in the omicron era. New Microbiol. 2022; 45(4):355-357. View

11.

Killander Moller I, Gisslen M, Wagner P, Sparen P, Carlander C . COVID-19 hospitalization outcomes in adults by HIV status; a nation-wide register-based study. HIV Med. 2023; 24(10):1045-1055. DOI: 10.1111/hiv.13515. View

12.

Fenwick C, Joo V, Jacquier P, Noto A, Banga R, Perreau M . T-cell exhaustion in HIV infection. Immunol Rev. 2019; 292(1):149-163. PMC: 7003858. DOI: 10.1111/imr.12823. View

13.

Ruddy J, Boyarsky B, Werbel W, Bailey J, Karaba A, Garonzik-Wang J . Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV. AIDS. 2021; 35(11):1872-1874. PMC: 10323866. DOI: 10.1097/QAD.0000000000002945. View

14.

Choy K, Wong A, Kaewpreedee P, Sia S, Chen D, Hui K . Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020; 178:104786. PMC: 7127386. DOI: 10.1016/j.antiviral.2020.104786. View

15.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

16.

Kunisaki K, Janoff E . Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009; 9(8):493-504. PMC: 2775097. DOI: 10.1016/S1473-3099(09)70175-6. View

17.

Bloomfield G, Khazanie P, Morris A, Rabadan-Diehl C, Benjamin L, Murdoch D . HIV and noncommunicable cardiovascular and pulmonary diseases in low- and middle-income countries in the ART era: what we know and best directions for future research. J Acquir Immune Defic Syndr. 2014; 67 Suppl 1:S40-53. PMC: 4133739. DOI: 10.1097/QAI.0000000000000257. View

18.

Bertagnolio S, Thwin S, Silva R, Nagarajan S, Jassat W, Fowler R . Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19. Lancet HIV. 2022; 9(7):e486-e495. PMC: 9090268. DOI: 10.1016/S2352-3018(22)00097-2. View

19.

Khan K, Lustig G, Bernstein M, Archary D, Cele S, Karim F . Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV). Clin Infect Dis. 2021; 75(1):e857-e864. PMC: 8689810. DOI: 10.1093/cid/ciab1008. View

20.

Favara G, Barchitta M, Maugeri A, Faro G, Agodi A . HIV infection does not affect the risk of death of COVID-19 patients: A systematic review and meta-analysis of epidemiological studies. J Glob Health. 2022; 12:05036. PMC: 9380965. DOI: 10.7189/jogh.12.05036. View